Skip to main content

Immunovia, Linköping University Collaborate on Autoimmune Disease

NEW YORK (360Dx) – Immunovia today announced it has signed a research collaboration deal with Linköping University to discover autoimmine disease diagnostic biomarkers.

The deal with the university's faculty of medicine and health sciences aims to accelerate the development of new diagnostic tests using Immunovia's Immray antibody array platform. Specifically, it targets rheumatoid arthritis, primary Sjögren’s syndrome, systemic lupus erythematosus (SLE), and vasculitis.

Immunovia said the agreement complements a collaboration it already has with Lund University by providing access to biobanks of clinically well-document samples and extensive autoimmune disease expertise. Financial and other terms of today's deal were not disclosed.

"There is a major need for differential diagnostics in this area, and we believe [the] Immray platform is particularly suited to develop accurate, rapid, and reliable patient diagnostics to enable better patient management," Immunovia CEO Mats Grahn said in a statement. He added that the firm's Immray SLE-d has demonstrated differential diagnostic accuracy of greater than 95 percent.

Earlier this year, the company said that it was able to distinguish patients suffering from SLE from those with other autoimmune diseases using the Immray platform.